Received Feb 19, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | M4B34 | IM / LA |
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | M4B34 | IM / LA |
Pharmacist printed out ADR and VIS to give to patient and counseled on possible side effects that may occur. Patient was told to self-monitor over the next 24 to 48 hours and to go to ER if ADRs intensify.
None reported
None reported
None reported
None reported
None reported